Cargando…
The Estrogen Receptor Joins Other Cancer Biomarkers as a Predictor of Outcome
Endometrial cancer, the most common gynecologic malignancy in the United States, is on the rise, and survival is worse today than 40 years ago. In order to improve the outcomes, better biomarkers that direct the choice of therapy are urgently needed. In this review, we explore the estrogen receptor...
Autores principales: | Leslie, Kimberly K., Thiel, Kristina W., Reyes, Henry D., Yang, Shujie, Zhang, Yuping, Carlson, Matthew J., Kumar, Nirmala S., Dai, Donghai D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3816067/ https://www.ncbi.nlm.nih.gov/pubmed/24223042 http://dx.doi.org/10.1155/2013/479541 |
Ejemplares similares
-
Role of metadherin in estrogen-regulated gene expression
por: Li, Yujun, et al.
Publicado: (2017) -
Inverse Relationship between Progesterone Receptor and Myc in Endometrial Cancer
por: Kavlashvili, Tamar, et al.
Publicado: (2016) -
Systematic dissection of the mechanisms underlying progesterone receptor downregulation in endometrial cancer
por: Yang, Shujie, et al.
Publicado: (2014) -
Knockdown of MTDH Sensitizes Endometrial Cancer Cells to Cell Death Induction by Death Receptor Ligand TRAIL and HDAC Inhibitor LBH589 Co-Treatment
por: Meng, Xiangbing, et al.
Publicado: (2011) -
Past, present, and future of hormonal therapy in recurrent endometrial cancer
por: Carlson, Matthew J, et al.
Publicado: (2014)